Navigation Links
Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
Date:6/1/2009

Move strengthens Kendle's position as a global clinical development partner to the biopharmaceutical industry

CINCINNATI, June 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the opening of offices in Kuala Lumpur, Malaysia; Bangkok, Thailand; and Manila, Philippines. The new operations provide Kendle's global biopharmaceutical customers with access to additional patient populations while strengthening the Company's position as a global clinical development partner. Kendle has been active in the Asia/Pacific region since 1998 and currently operates offices in Beijing, Hong Kong and Shanghai, China; New Delhi and Ahmedabad, India; Singapore; and Sydney and Melbourne, Australia.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Kendle is one of the few truly global providers offering comprehensive Phase I-IV solutions to meet the needs of the world's biopharmaceutical industry," said Candace Kendle, PharmD, Chairman and CEO. "Our expanded presence in the Asia/Pacific region enhances opportunities for patient access, creates efficiencies in the clinical development process and overall strengthens Kendle's ability to foster global strategic alliances with the leading companies in the biopharmaceutical industry."

Kendle's expansion in Asia/Pacific reflects the growing importance of the region to the global clinical research market. Recent research by the Tufts Center for the Study of Drug Development indicates that within the next three years, as much as 65 percent of all FDA-regulated clinical trials will be conducted outside the United States, with a significant number of these studies moving to Asia. Clinical research organizations with a sound understanding of the Asian marketplace will have a sizeable advantage.

"With more than half of the world's population, Asia offers an abundance of patients in nearly every therapeutic area," added Dr. Ross Horsburgh, Vice President, Global Clinical Development - Asia/Pacific. "Furthermore, governments have highlighted biopharmaceutical development as a key pillar to their economies, resulting in much more favorable environments for global clinical development work."

The new Kendle offices are located at:

    Kendle Sdn Bhd
    Level 16, 1 Sentral
    Jalan Stesen Sentral 5
    KL Sentral, 50470
    Kuala Lumpur
    Malaysia

    Kendle C.R.O. (Thailand) Co., Ltd.
    23/F M Thai Tower, All Seasons Place
    87 Wireless Road
    Lumpini, Phatumwan
    Bangkok 10330 Thailand

    Kendle CRO Philippines, Inc.
    18th Floor Philamlife Tower
    8767 Paseo de Roxas
    Makati City 1226, Philippines

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements include, but are not limited to Kendle's existing and planned growth and market penetration in the Asia Pacific region, including India. Kendle cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include (a) fluctuation in the exchange rate of the U.S. dollar to other currencies; (b) the ability to set up and sustain growth entities in the above described regions; (c) changes in the markets for the company's service offerings; (d) changes in the market for customers' products; and (e) other risks as detailed from time to time in Kendle's SEC reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Annual Reports on Form 10-K.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces First Quarter 2009 Results
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
4. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
5. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
6. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
7. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
8. Kendle to Present at the 2008 Credit Suisse Health Care Conference
9. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
10. Kendle Named a Best Place to Work in Greater Cincinnati
11. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ -  Equicare Health ... solutions, has been recognized as one of the top ... an annual international listing that distinguishes the top digital ... pushed a great step forward this year continually upgrading ... our own customer base and team," says Len ...
(Date:11/30/2016)... Massachusetts , 30. November 2016 /PRNewswire/ ... Technologieunternehmen, hat heute die Unterzeichnung einer Reihe ... Diesen zufolge wird Evotec AG Screeningleistungen für ... shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese Bibliotheken ... Screening eröffnet einen schnelleren Weg zur Ermittlung ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in ... implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... MA. , The event follows the successful November 15th event that took ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
Breaking Biology News(10 mins):